SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001683168-23-007992
Filing Date
2023-11-13
Accepted
2023-11-13 17:00:18
Documents
15
Period of Report
2023-12-06

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT xenetic_def14a.htm   iXBRL DEF 14A 398123
6 GRAPHIC image_001.jpg GRAPHIC 116461
7 GRAPHIC image_002.jpg GRAPHIC 153220
  Complete submission text file 0001683168-23-007992.txt   1523870

Data Files

Seq Description Document Type Size
2 XBRL SCHEMA FILE xbio-20221231.xsd EX-101.SCH 4140
3 XBRL DEFINITION FILE xbio-20221231_def.xml EX-101.DEF 7236
4 XBRL LABEL FILE xbio-20221231_lab.xml EX-101.LAB 53999
5 XBRL PRESENTATION FILE xbio-20221231_pre.xml EX-101.PRE 41828
10 EXTRACTED XBRL INSTANCE DOCUMENT xenetic_def14a_htm.xml XML 61495
Mailing Address 945 CONCORD ST. FRAMINGHAM MA 01701
Business Address 945 CONCORD ST. FRAMINGHAM MA 01701 781-778-7720
Xenetic Biosciences, Inc. (Filer) CIK: 0001534525 (see all company filings)

IRS No.: 452952962 | State of Incorp.: NV | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-37937 | Film No.: 231399819
SIC: 2834 Pharmaceutical Preparations